share_log

HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $16

Benzinga ·  Oct 26, 2023 06:42

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $13 to $16.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment